Evidence map›Paper›PMID 34981468›Full record

Trial reportAdvances in experimental medicine and biology2021

Curcumin and Piperine Combination for the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Trial.

Seyed Reza Mirhafez, Maryam Dehabeh, Mitra Hariri, Azam Rezaie Farimani, Ali Movahedi, Ronika Danesh Naderan, Tannaz Jamialahmadi, Luis E Simental-Mendía, Amirhossein Sahebkar

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
28.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Seyed Reza MirhafezNoncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Maryam DehabehNoncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Mitra HaririNoncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Azam Rezaie FarimaniNoncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Ali MovahediDepartment of Anesthesia and Operating Room Nursing, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Ronika Danesh NaderanNoncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Tannaz JamialahmadiDepartment of Food Science and Technology, Quchan Branch, Islamic Azad University, Quchan, Iran.
Luis E Simental-MendíaBiomedical Research Unit, Mexican Social Security Institute, Durango, Mexico.
Amirhossein SahebkarBiotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir.
Non-Communicable Diseases Research CenterUniversity of Neyshabur · IRBiotechnology Research Center · IRMashhad University of Medical Sciences · IRMexican Social Security Institute · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExperimental and clinical studies have revealed that curcumin may be an effective therapy for non-alcoholic fatty liver disease (NAFLD). Hence, the aim of this study was to assess the effect of curcumin plus piperine administration on NAFLD.

methodsAdults 18-65 years-old diagnosed with NAFLD by liver sonography were randomly allocated to curcumin (500 mg/day) or placebo groups for 2 months. All participants received both dietary and exercise advice. Anthropometric and biochemical measurements as well as hepatic ultrasound were performed at baseline and final conditions.

resultsSeventy-nine participants were recruited and randomly allocated into the curcumin (n = 39) or placebo (n = 40) groups. There were no significant differences between placebo and curcumin groups for demographic and clinical characteristics and NAFLD grade at baseline. After the treatment period, the curcumin group exhibited lower alkaline phosphatase (-16.2 ± 22.8 versus -6.0 ± 22.5 mg/dL, p = 0.04) concentrations and severity of NAFLD compared with the placebo group (p = 0.04).

conclusionResults of this clinical trial suggest that short-term treatment with curcumin plus piperine administration improves NAFLD severity.

Indexed as

CurcuminNon-alcoholic Fatty Liver DiseaseAdolescentAdultAgedAlkaloidsBenzodioxolesDietary SupplementsDouble-Blind MethodHumansLiverMiddle AgedPiperidinesPolyunsaturated AlkamidesYoung AdultAlkaloidsBenzodioxolesCurcuminPiperidinespiperinePolyunsaturated AlkamidesClinical trialCurcuminFatty liver diseasePiperineSteatosis

Identifiers

PMID34981468
OpenAlexW4205097203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.